Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06163898 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Celgene.
- Active
- Registry status
- Phase 1
- Development phase
- 156
- Enrollment target
- 6
- Study locations
NCT06163898: Active Phase 1 study of Multiple Myeloma, sponsored by Celgene.
NCT06163898 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Celgene. The registered enrollment target is 156 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (71% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06163898, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Celgene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 156 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Mezigdomide
- DRUG Alnuctamab
Study Locations (6)
Central District
- Local Institution - 0021 - Petah Tikva
- Local Institution - 0030 - Ramat Gan
Alabama
- Local Institution - 0033 - Birmingham
Connecticut
- Local Institution - 0035 - New Haven
New York
- Local Institution - 0018 - New York
Other
- Local Institution - 0020 - Jerusalem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2024-02-27 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 1 |
What the registry record for NCT06163898 still lists
NCT06163898 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT06163898 lists 6 locations in 5 states (Central District, Alabama, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06163898 about?
NCT06163898 is a clinical study titled "A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma". The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.
What is the current status of trial NCT06163898?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2024-02-27. Estimated completion is 2025-05-30.
What conditions does trial NCT06163898 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06163898?
The interventions under investigation include: Dexamethasone (DRUG), Mezigdomide (DRUG), Alnuctamab (DRUG).
Who is sponsoring clinical trial NCT06163898?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06163898 being conducted?
This trial has 6 study locations across Alabama, Connecticut, New York, Central District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06163898's enrollment target sits among peer trials
156 130th of 438 higher than 308 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI